Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275135 | 0.81 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL5850255 | 0.75 | NPC1 (0.79) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL2530865 | 0.73 | GPR84 (0.67) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL405311 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL74304 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL6017338 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL130519 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL228554 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL130518 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL18805065 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372334-A | 2- (4-methionyl) anilino-4-amino-5-trifluoromethylpyrimidine derivatives and application thereof | 贵州医科大学 | 2021-09-10 | — | — | CN | claimed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | claimed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | claimed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-RE43098-E1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | claimed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | claimed |
| EP-2277877-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-26 | — | — | EP | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | claimed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002036587-A2 | PROCESS FOR THE PRODUCTION OF 4-QUINAZOLINYLPIPERAZIN-1-CARBOXYLIC ACID PHENYLAMIDES | COR THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | NME1, NME2, TNNI3K | AHR 3059/4885NR4A2 2665/4885CYP2A6 2048/4885 |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885NR4A2 2706/4885CYP2A6 4175/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885NR4A2 2706/4885CYP2A6 4175/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | AHR 1321/4885NR4A2 816/4885CYP2A6 2117/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885NR4A2 2706/4885CYP2A6 4175/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | AHR 562/4885NR4A2 1704/4885CYP2A6 2654/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | AHR 1824/4885NR4A2 844/4885CYP2A6 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.